Jan Moritz M.
- Country
- Germany
- Department
- Medizinische Klinik und Poliklinik I
Research Overview
- MRD-Guided Pembrolizumab and Azacitidine Therapy in NPM1-Mutated Acute Myeloid Leukemia with Imminent Hematological Relapse
- Phase 3 Evaluation of Venetoclax and Azacitidine Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients
- Extended Access Study of Momelotinib Dihydrochloride Monohydrate in Patients with Primary Myelofibrosis or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Data & Insights
Has run more than one trial at 33 of 204 partner sites.
Specializations
Acute Myeloid Leukemia Focus
This investigator demonstrates significant expertise in treating acute myeloid leukemia (AML), with particular emphasis on molecular relapse management and post-transplantation care.
- MRD-guided therapeutic approaches
- Combination therapy strategies
- Post-transplant maintenance therapy
Their work extends to investigating novel therapeutic combinations involving azacitidine and targeted agents for AML treatment.
Lymphoid Malignancies
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with focus on innovative treatment duration strategies.
- MRD-guided treatment protocols
- Fixed-duration therapy approaches
- Novel therapeutic combinations
Their research explores personalized treatment durations based on individual disease response patterns.
Myeloid Disorders
The investigator has expertise in treating myelofibrosis and related conditions including post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
- Primary myelofibrosis management
- Long-term disease monitoring
- Advanced therapeutic approaches
Their work includes evaluation of extended access treatments for patients with various forms of myelofibrosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.